Jump to main navigation | Jump to sub navigation | Jump to SiteMap | Jump to Home Page |
Latest News Releases
News and features
Epistem’s Radiation Damage Models for Intestinal Stem Cells Chosen by NIH Biodefence ProgrammeEpistem Ltd announced today that it has been selected to provide in vivo efficacy testing services for the U.S. National Institutes of Health's (NIH) research programme on Medical Countermeasures Against Radiological and Nuclear Threats.
13/12/2006
Epistem signs agreement with Eden BiodesignEpistem, a private Manchester based biotechnology company, announced today that it has entered into a contract manufacturing agreement with Eden Biodesign (Liverpool, UK), a leading provider of support and manufacturing services for the pharmaceutical research industry.
24/10/2006
Unique partnership that will help develop new drug to treat mucositis in cancer patients.Japanese firm Kyowa Hakko Kogyo is pioneering new treatment for the prevention of mucositis, a painful condition associated with the treatment of cancer, thanks to Manchester based company Epistem Ltd.
19/6/2006
Applied Imaging Completes First Custom Installation of Ariol(R) Image Analysis System at Preclinical Research Provider EpiStem, Ltd.Applied Imaging Corp. (OTC Bulletin Board: AICX), or "Applied Imaging" or the "Company," today announced the successful installation of one of its customized Ariol(R) SL-50 automated imaging systems at Epistem Ltd., an independent contract research company focused on preclinical epithelial tissue analysis.
31/5/2006
Callisto Pharmaceuticals selects EpiStem to provide specialised preclinical efficacy testing for Guanilib, its lead drug candidate for IBD.Epistem Ltd announced today that it has been selected by Callisto Pharmaceutials, Inc to provide specialised preclinical efficacy testing in the area of inflammatory bowel disease (IBD).
15/5/2006
